Manufacturing peptides as active pharmaceutical ingredients.
about
Advances in Fmoc solid-phase peptide synthesisAutomated solid-phase peptide synthesis to obtain therapeutic peptidesAmphiphilic peptides and their cross-disciplinary role as building blocks for nanoscienceThe Pharmaceutical Industry in 2016. An Analysis of FDA Drug Approvals from a Perspective of the Molecule Type.Metastasis: recent discoveries and novel perioperative treatment strategies with particular interest in the hemostatic compound desmopressin.Investigation the Possibility of Using Peptides with a Helical Repeating Pattern of Hydro-Phobic and Hydrophilic Residues to Inhibit IL-10.Reduction of tumor angiogenesis induced by desmopressin in a breast cancer modelChallenging the catechism of therapeutics for chronic neuropathic pain: Targeting CaV2.2 interactions with CRMP2 peptides.Non-invasive iontophoretic delivery of peptides and proteins across the skin.New modalities in conformationally constrained peptides for potency, selectivity and cell permeation.Solid-phase peptide synthesis (SPPS), C-terminal vs. side-chain anchoring: a reality or a myth.Resetting the autoreactive immune system with a therapeutic peptide in lupus.Review cyclic peptides on a merry-go-round; towards drug design.Nanomaterials, Autophagy, and Lupus Disease.Investigation of cytotoxicity of negative control peptides versus bioactive peptides on skin cancer and normal cells: a comparative study.Antiproliferative effect of 1-deamino-8-D-arginine vasopressin analogs on human breast cancer cells.Enzymatic stability, solution structure, and antiproliferative effect on prostate cancer cells of leuprolide and new gonadotropin-releasing hormone peptide analogs.Production of the short peptide surfactant DAMP4 from glucose or sucrose in high cell density cultures of Escherichia coli BL21(DE3).2-Methyltetrahydrofuran and cyclopentyl methyl ether for green solid-phase peptide synthesis.Molecular design and synthesis of self-assembling camptothecin drug amphiphiles.New t-butyl based aspartate protecting groups preventing aspartimide formation in Fmoc SPPS.Synthesis of Reusable Silica Nanosphere-Supported Pt(IV) Complex for Formation of Disulfide Bonds in Peptides.Therapeutic peptides.In silico approaches for predicting the half-life of natural and modified peptides in blood.RADA-16: A Tough Peptide - Strategies for Synthesis and PurificationFmoc Methodology: Cleavage from the Resin and Final Deprotection
P2860
Q26770921-1D3EC974-C5C6-4E7F-A209-64C65D83ECC8Q27001623-C55906D0-7746-4CE1-9B6A-E5C604D61EBEQ29028236-40129EFF-8A8C-4790-9F2F-57BB290D7E6EQ34552756-87664D36-8FB4-4D2C-AA2E-939C688B5953Q35671216-92FE7376-8DB1-41F1-B538-CFF474AEACC7Q35995841-1BA4AF32-4229-478C-8B80-80AAE2BEEB48Q37302108-96D62EFD-1D9B-4DE0-A9FD-5B8337E2FCBBQ37360619-E8AB7609-7AB0-4A8F-8D57-C786DAA08928Q37856312-0BD7A844-BF9B-4AB6-88CD-EC557D727E69Q38104757-CDBBD70A-FC63-49CA-B54D-791FE26966A7Q38207510-6D686EFD-C1DD-4372-A408-C4CB679B0885Q38388415-C8542AA1-1837-4081-8FD3-476C032E5E05Q38476515-DC6DC411-A3CE-443C-81F6-0D90ED488BAFQ38551098-2BDB5366-8794-4852-B756-E70E9C2D440CQ39292187-AE35FA9E-35C1-4C8C-BE26-4314A306066BQ39440666-96B47ADD-95A8-434C-9C62-53B955E34050Q39679939-A0758ADF-6616-4F52-A8EB-FC8663B17DE0Q43003057-DEC78024-AD64-401E-9A1C-517150C1348AQ50244271-0089AC47-1660-4A21-9920-701BA7DAB546Q50682565-0508801B-601D-419D-B974-E66F75F5B559Q50963132-836D3467-D78E-4B1E-857F-3ACD056C070AQ50988011-9009D706-BD64-4C62-B408-D84DAB089A3BQ51564495-1C531DE4-69AE-41CD-A725-3D8FDDE1C117Q55170817-3EB6A6BE-7977-46CF-986A-F13163F1DC96Q58035063-E1112869-5602-4DBE-812F-36E9C7F215F1Q58035119-77832D4F-7807-4733-882D-3C1FDBA446B2
P2860
Manufacturing peptides as active pharmaceutical ingredients.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Manufacturing peptides as active pharmaceutical ingredients.
@en
Manufacturing peptides as active pharmaceutical ingredients.
@nl
type
label
Manufacturing peptides as active pharmaceutical ingredients.
@en
Manufacturing peptides as active pharmaceutical ingredients.
@nl
prefLabel
Manufacturing peptides as active pharmaceutical ingredients.
@en
Manufacturing peptides as active pharmaceutical ingredients.
@nl
P2860
P50
P356
P1476
Manufacturing peptides as active pharmaceutical ingredients
@en
P2093
Oleg Werbitzky
P2860
P304
P356
10.4155/FMC.09.23
P577
2009-05-01T00:00:00Z